RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancerCristina Cruz, Violeta Serra, Marta Castroviejo‐Bermejo et al.|Annals of Oncology|2018Cited by 424
Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upAntonio González-Martı́n, Jonathan A. Ledermann, Philipp Harter et al.|Annals of Oncology|2023Cited by 381
ESGO–ESMO–ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent diseaseJonathan A. Ledermann, Anna Fagotti, Sabrina Croce et al.|Annals of Oncology|2024Cited by 277
Antitumor Activity and Safety of Dostarlimab Monotherapy in Patients With Mismatch Repair Deficient Solid TumorsThierry André, Susana Banerjee, Dominique Berton et al.|JAMA Network Open|2023Cited by 120
Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET StudyAna Oaknin, Anna V. Tinker, Bhavana Pothuri et al.|Clinical Cancer Research|2023Cited by 80